Las Vegas, NV -- (SBWIRE) -- 12/19/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Unwired Planet Inc (NASDAQ:UPIP), Andatee China Marine Fuel Ser Corp (NASDAQ:AMC), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), China Ming Yang Wind Power Group Ltd (NYSE:MY)
Unwired Planet Inc (NASDAQ:UPIP) opened the session at $1.34, trading in a range of $1.34 - $1.48, and closed at $1.45. The stock showed a positive performance of +9.02% in the last trading session. The stock traded on a volume of 1.17 million shares and the average volume of the stock remained 338,012 shares. Unwired Planet, Inc. develops patents that allow mobile devices to connect to the Internet. Its patent portfolio consists of approximately 200 issued United States and foreign patents, and approximately 60 pending applications that cover technologies applicable to the mobile industry.
Will UPIP Continue To Move Higher? Find Out Here
Andatee China Marine Fuel Ser Corp (NASDAQ:AMC) traded 1.17 million shares in the last business day while the average volume of the stock remained 197,099 shares. The stock showed a positive movement of +24.83% to end at $1.86. The 52 week range of the stock remained $1.50 - $1.90. Andatee China Marine Fuel Services Corporation, through its subsidiaries, engages in the production, storage, distribution, and trading of blended marine fuel oil for cargo and fishing vessels in the People?s Republic of China. It also produces customer specific products using its proprietary blending technology.
For How Long AMC will fight for Profitability? Read This Trend Analysis report
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) reported 1.15 million shares were exchanged during the last trade, while the average volume is about 4.25 million shares. The stock dropped -8.39% and finished the day at $4.26. The beta of the stock is recorded at 0.50. Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States. It develops Oxycyte, a systemic perfluorocarbon based oil in water emulsion oxygen carrier for use in situations of acute ischemia; and is in Phase II-b clinical trial for the treatment of traumatic brain injury.
Why Should Investors Buy OXBT After the Recent Fall? Just Go Here and Find Out
China Ming Yang Wind Power Group Ltd (NYSE:MY) the stock advanced +3.98% and finished the session at $2.09.Traded with volume of 1.14 million shares in the prior session and the average volume of the stock remained 1.13 million shares. China Ming Yang Wind Power Group Limited engages in designing, manufacturing, selling, leasing, and servicing megawatt-class, grid-connected, and horizontal-axis wind turbines primarily in the People?s Republic of China.
Will MY Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)